Abstract
BACKGROUND: Aerosol drug delivery to infants and small children is influenced by many factors, such as types of interface, gas flows, and the designs of face masks. The purpose of this in vitro study was to evaluate aerosol delivery during administration of gas flows across the range used clinically with high-flow humidity systems using 2 aerosol masks.
METHODS: A spontaneous lung model was used to simulate an infant/young toddler up to 2 y of age and pediatric breathing patterns. Nebulized salbutamol by a vibrating mesh nebulizer positioned at the inlet of a high-flow humidification system at gas flows of 3, 6, and 12 L/min was delivered via pediatric face masks to a pediatric face mannequin attached to a filter. Aerosol particle size distribution exiting the vibrating mesh nebulizer and at the mask position distal to the heated humidifier with 3 flows was measured with a cascade impactor. Eluted drug from the filters and the impactor was analyzed with a spectrophotometer (n = 3). Statistical analysis was performed by analysis of variance with a significant level of P < .05.
RESULTS: The inhaled mass was between 2.8% and 8.1% among all settings and was significantly lower at 12 L/min (P = .004) in the pediatric model. Drug delivery with pediatric breathing was greater than with infant breathing (P = .004). The particle size distribution of aerosol emitted from the nebulizer was larger than the heated humidified aerosol exiting the tubing (P = .002), with no difference between the 3 flows (P = .10).
CONCLUSIONS: The flows of gas entering the mask and breathing patterns influence aerosol delivery, independent of the face mask used. Aerosol delivery through a high-flow humidification system via mask could be effective with both infant and pediatric breathing patterns.
- pediatric
- aerosol delivery
- high-flow humidification
- aerosol mask
- gas flows
- particle size distribution
- vibrating mesh nebulizer
Footnotes
- Correspondence: Hui-Ling Lin MSc RRT RN FAARC, Respiratory Therapy Program, College of Medicine, Chang Gung University, 259 Wen-Haw 1st, Kwei-Shan, Taoyuan, Taiwan, Republic of China. E-mail: huilingrrt{at}gmail.com
This joint research project was developed under a Memorandum of Cooperation between Chang Gung University and Georgia State University to promote international cooperation in education and research.
Ms Lin presented a version of this paper in an open forum section of the 58th International Respiratory Congress, held November 10–13, 2012, in New Orleans, Louisiana.
Dr Fink is a consultant to Aerogen, Ansun, Bayer, Boerhinger Ingleheim, Dance Biopharm, Novartis, Ony, Parion, Aridis, and the World Health Organization. The other authors have disclosed no conflicts of interest.
See the Related Editorial on Page 1365
- Copyright © 2015 by Daedalus Enterprises